Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-007 plus tislelizumab with chemotherapy for unresectable locally advanced or metastatic esophageal squamous cell carcinoma (Phase II)
CTR20233227Phase 2Completed
- Sponsor
- BeiGene
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alcestobart in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Started Oct 2023; status: completed.
02
Drugs
alcestobart
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20233227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233227.